Cortés, AlfonsoLópez-Miranda, ElenaFernández-Ortega, AdelaCarañana, VicenteServitja Tormo, SoniaUrruticoechea, AnderLema-Roso, LauraMárquez, AntoniaLazaris, AlexandrosAlcalá-López, DanielMina, LeonardoGener, PetraRodríguez-Morató, Jose, 1987-Antonarelli, GabrieleLlombart-Cussac, AntonioPérez-García, JoséCortés, Javier2025-10-222025-10-222024Cortés A, López-Miranda E, Fernández-Ortega A, Carañana V, Servitja S, Urruticoechea A, Lema-Roso L, Márquez A, Lazaris A, Alcalá-López D, Mina L, Gener P, Rodríguez-Morató J, Antonarelli G, Llombart-Cussac A, Pérez-García J, Cortés J. Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 study. Breast. 2024 Dec;78:103834. DOI: 10.1016/j.breast.2024.1038340960-9776http://hdl.handle.net/10230/71633Purpose: To evaluate olaparib in advanced triple negative breast cancer (TNBC) patients with homologous recombination deficiency (HRD) and no germline BRCA1/2 mutations (gBRCA1/2mut). Methods: NOBROLA (NCT03367689) is a single-arm, open-label, multicenter, phase IIa trial, enrolling adult patients with advanced TNBC without gBRCA1/2mut and with HRD, who were treated with olaparib. The primary endpoint was clinical benefit rate (CBR) per RECIST v.1.1. Results: Six of 114 patients were eligible and received olaparib. Median follow up was 8.5 months. CBR and overall response rate (ORR) were 50 % (95 % CI, 11.8-88.2). Conclusions: The observed results could prompt further investigation. Trial: ClinicalTrials.gov identifier NCT03367689.application/pdfeng© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).info:eu-repo/semantics/article2025-10-22http://dx.doi.org/10.1016/j.breast.2024.103834Germline BRCA1/2 mutationsHomologous recombination deficiencyOlaparibPARP inhibitorsTriple-negative breast cancerinfo:eu-repo/semantics/openAccess